{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for phenyl root_names_stdName in Standardized Name (approximate match)
Status:
Investigational
Source:
NCT00838461: Phase 1 Interventional Completed Healthy Subjects
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
HSD-016 was discovered as an orally efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitor for the treatment of diabetes. The phase I in clinical trials for the drug was completed; however, information about further studies is not available.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
NCT00644488: Phase 1 Interventional Completed Prostate Cancer
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Bristol-Myers Squibb developed BMS-641988 as a nonsteroidal androgen receptor antagonist for the treatment of prostate cancer. BMS-641988 participated in phase I clinical trials in patients with castration-resistant prostate cancer in Japan and in the USA. However, further information is not available.
Status:
Investigational
Source:
NCT03037645: Phase 1/Phase 2 Interventional Terminated Chronic Lymphocytic Leukemia
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
NCT00712829: Phase 1 Interventional Completed Prostate Cancer
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
MIP-1095 I-123 is under investigation in clinical trial phase II to evaluate the safety and efficacy in combination with enzalutamide in patients with prostate-specific membrane antigen (PSMA)-avid metastatic castration-resistant prostate cancer who have progressed on abiraterone. It is known that MIP-1095 potently inhibited the glutamate carboxypeptidase activity of PSMA and when radiolabeled with 123I exhibited high affinity for prostate-specific membrane antigen (PSMA) on human prostate cancer LNCaP cells.
Status:
Investigational
Source:
NCT01473056: Phase 1 Interventional Completed Hepatitis C Virus Infection, Response to Therapy of
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
JTK-853, a piperazine derivative, is a non-nucleoside inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase. It is under development for the treatment of hepatitis C virus infection.
Status:
Investigational
Source:
NCT00606749: Phase 2 Interventional Completed Pemphigus Vulgaris
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
ITX-5061, an arylketoamide derivative, is a scavenger receptor B1 antagonist and a potent hepatitis C virus (HCV) entry inhibitor. It entered phase I clinical trial in liver transplant recipients with HCV but the trial was terminated.
Status:
Investigational
Source:
NCT04173065: Phase 2 Interventional Completed NASH - Nonalcoholic Steatohepatitis
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
MB-07811 (VK-2809) is the liver-activated prodrug of a phosphonate-containing thyroid hormone receptor beta agonist MB-07344. In animal studies, it showed potent lipid and cholesterol lowering activity. Viking Therapeutics is developing MB-07811 hypercholesterolaemia and non-alcoholic fatty liver disease.
Status:
Investigational
Source:
NCT00258622: Phase 2 Interventional Completed Pain
(2005)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
NCT00972504: Phase 2 Interventional Completed Rhinitis, Allergic, Seasonal
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
